- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Isis Pharmaceuticals Inc
+ Add to WatchlistISIS:US
20.9800 USD 0.3400 1.65%
Share
As of 20:10:00 ET on 05/24/2013.
More on ISIS
News for Isis Pharmaceuticals Inc (ISIS)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- AstraZeneca CEO Chases Multiple Strands in RNA Drug Quest
- Sanofi Obtains EU Panel Recommendation for MS Tablet Aubagio
- U.S. Stock Options With Biggest Changes in Implied Volatility
- U.S. Stock Options With Biggest Changes in Implied Volatility
- The Top Ten Stocks for Wednesday, January 30
- Sanofi, Isis Win FDA Approval for Hyper-Cholesterol Drug
- Aegerion Rare-Disease Drug Wins U.S. Regulatory Approval
- Sanofi Cholesterol Drug With Isis Fails to Win EU Backing
- Aegerion Drug Wins Panel Support for Cholesterol Disease
- Isis Falls on Concerns Over Abnormal Growths With Kynamro
- Aegerion Shares Rise on Report of High Cholesterol Drug
- Toddlers Facing Heart Attacks Await Ruling on New Drugs
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Implied Stock-Price Moves for U.S. Companies Reporting Results
- Implied Stock-Price Moves for U.S. Companies Reporting Results
- Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference Published May 23, 2013
- The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Published May 16, 2013
- Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference Published May 13, 2013
- Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec Published May 09, 2013
- Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference Published May 09, 2013
- Isis Pharmaceuticals Prices Public Offering Of Common Stock Published May 09, 2013
- Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock Published May 07, 2013
- Isis Reports Financial Results and Highlights for First Quarter 2013 Published May 07, 2013
- Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer Published May 06, 2013
- Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call Published May 02, 2013
- China’s Stocks Rise After Biggest Slump in a Month
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- BioMarin Gains on Prospects for Experimental Cancer Drug
- Kasowitz Benson, Eversheds, Latham: Business of Law
- Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal
- ‘Love Hormone’ Promises Safer Births After Pfizer Flop
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Actavis to Buy Warner Chilcott in Women’s Health Effort
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- Elan Makes Two Acquisitions for $380 Million
- ThromboGenics Reports Jetrea Sales as Drug Fails Mid-Stage Study
- Eu Yan Sang Jumps Most Since Feb. 2012 on Deal: Singapore Mover
- Algeta Surges to Record After Prostate Cancer Drug Approval
- Teva U.S. Jump Widens Holiday Discount: Israel Overnight
- Chesapeake Partners Holdings in 1st Quarter: 13F Alert
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page